Can patients with advanced liver cancer be treated with cabozantinib?

Liver cancer is a highly aggressive cancer. Especially in the advanced stage, treatment options are relatively limited, which greatly affects the patient's survival and quality of life. In recent years, with the rapid development of targeted therapy, cabozantinib (Cabozantinib), as a new targeted drug, has been proposed as a potential treatment option for advanced liver cancer. So, can patients with advanced liver cancer use cabozantinib? This article will discuss it from multiple perspectives such as drug mechanism, clinical research, and indications.

Cabozantinib is a multi-target small molecule targeted drug that mainly exerts anti-tumor effects by inhibiting multiple signaling pathways, including VEGFR (vascular endothelial growth factor receptor), MET (hepatocyte growth factor receptor) and AXL, etc. Through these effects, cabozantinib can not only effectively inhibit the growth and metastasis of tumor cells, but also improve angiogenesis in the tumor microenvironment, achieving the effect of slowing down tumor development. Because the occurrence and development of liver cancer are closely related to these pathways, cabozantinib has become a new treatment option for patients with advanced liver cancer.

In terms of clinical research, the application of cabozantinib in the treatment of advanced liver cancer has preliminary results. In 2018, cabozantinib was approved for the treatment of kidney cancer patients who had failed previous treatment, but with the deepening of research, its efficacy in liver cancer has gradually been verified. According to data from some clinical trials, cabozantinib has significant efficacy in patients with liver cancer, especially when combined with other treatments such as sorafenib, it can effectively improve the survival and remission rate of patients.

However, cabozantinib, as a targeted drug, is not suitable for all patients with advanced liver cancer. Its use requires a comprehensive assessment based on the patient's specific condition, especially the patient's liver function status and the presence of comorbidities. Cabozantinib has certain side effects, such as high blood pressure, diarrhea, abnormal liver function, etc., so it requires close monitoring and timely adjustment of the treatment plan during use.

Reference:https://en.wikipedia.org/wiki/Cabozantinib